RSS   Newsletter   Contact   Advertise with us
Post Online Media

Realm Therapeutics names Ivan Gergel as non-executive director

PuriCoreRealm Therapeutics, formerly PuriCore, a specialty biopharmaceutical company, announced that Ivan Gergel has been appointed as a non-executive director and will join the board on January 1, 2017.
Article continues below

READ MORE Petrobras names new investor relations executive manager

Dr. Gergel is currently Senior Vice President Drug Development and Chief Medical Officer at Nektar Therapeutics, a clinical-stage biopharmaceutical company based in San Francisco.

Prior to Nektar Therapeutics, Dr. Gergel held various positions in the biopharmaceutical industry.

Dr. Gergel was Executive Vice President R&D and Chief Scientific Officer at Endo Pharmaceuticals and a Senior Vice President R&D at Forest Laboratories (subsequently acquired by Actavis/Allergan) and has advanced multiple compounds from research through approval.

Dr. Gergel began his career as a practicing psychiatrist before moving to SmithKline Beecham Pharmaceuticals where he held several roles, including Group Director, CNS in the US.

He has been a Board member of Corium International since 2014.

His prior Committee memberships include PhRMA Foundation, Pennsylvania Bio and USA-India Chamber of Commerce Scientific Advisory Board.

Dr. Gergel received his MBA from the Wharton School at the University of Pennsylvania.

 LATEST MOVES FROM Pennsylvania 


We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy